局部术中唑来膦酸与术后地舒单抗均减轻非骨水泥全膝关节置换术的假体迁移:一项随机对照试验
该四臂双盲随机试验纳入108例原发性膝骨关节炎患者并随访五年,其中三组使用相同非骨水泥全膝关节胫骨假体(n=82),随机分为安慰剂组(n=27)、术中局部唑来膦酸组(n=28)和术后地舒单抗组(n=27)。两种抗骨吸收干预均通过抑制骨吸收减少非骨水泥胫骨假体迁移,局部唑来膦酸对假体下沉和假体周围骨密度有持久效果。作者认为 findings 支持在膝关节置换术中局部使用唑来膦酸以改善非骨水泥胫骨假体固定并保留胫骨骨量,但需多中心研究和前瞻性队列质量研究确认。
要点
- 术后一年唑来膦酸组与安慰剂组最大总点运动均值差0.43 mm(95%CI 0.01至0.85;p=0.043)。
- 术后一年地舒单抗组与安慰剂组最大总点运动均值差0.42 mm(95%CI 0.00至0.83;p=0.048)。
- 五年时干预组y轴平移(下沉)小于安慰剂组,唑来膦酸均值差0.50 mm(95%CI 0.23至0.78;p<0.001),地舒单抗均值差0.30 mm(95%CI 0.03至0.58;p=0.031)。
核心结论
- 两种干预均通过抑制骨吸收减少非骨水泥胫骨假体迁移,局部唑来膦酸对假体下沉和假体周围骨密度有持久减轻作用。
- 作者认为研究结果支持在膝关节置换术中局部使用唑来膦酸以改善非骨水泥胫骨假体固定并保留胫骨骨量。
- 作者指出需进行多中心研究和前瞻性队列质量研究以确认结果。
研究设计与样本
- 四臂双盲随机试验纳入108例原发性膝骨关节炎患者并随访五年,其中三组使用相同非骨水泥全膝关节胫骨假体并纳入本 primary 研究(n=82)。
- 患者随机分为安慰剂组(n=27)、术中局部唑来膦酸组(n=28)和术后地舒单抗组(n=27)。
- 主要结局为通过放射立体测量分析(RSA)测量的胫骨假体迁移,指标包括最大总点运动(MTPM)和有符号迁移。
- 次要结局为生化骨标志物(骨吸收:血清1型胶原交联C端肽(CTX);骨形成:血清1型前胶原N端前肽(P1NP))、假体周围骨密度和患者报告结局。
主要发现
- 术后一年唑来膦酸组与安慰剂组MTPM均值差0.43 mm(95%CI 0.01至0.85;p=0.043),地舒单抗组与安慰剂组MTPM均值差0.42 mm(95%CI 0.00至0.83;p=0.048)。
- 五年时干预组y轴平移(下沉)小于安慰剂组:唑来膦酸组均值差0.50 mm(95%CI 0.23至0.78;p<0.001),地舒单抗组均值差0.30 mm(95%CI 0.03至0.58;p=0.031)。
- 唑来膦酸组CTX在术后两周和六周随访时低于安慰剂组,地舒单抗组CTX在术后一年内低于安慰剂组。
- P1NP在安慰剂组与唑来膦酸组相似,但地舒单抗组在术后一年内低于安慰剂组。
- 假体周围骨密度在干预组较高,唑来膦酸组在五年时仍有持久效果。
临床怎么用
- 作者认为研究结果支持在膝关节置换术中局部使用唑来膦酸以改善非骨水泥胫骨假体固定并保留胫骨骨量。
- 作者指出需进行多中心研究和前瞻性队列质量研究以确认结果。
局限性
- 作者指出需进行多中心研究和前瞻性队列质量研究以确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to investigate if adjuvant treatment with antiresorptive bone medication improves fixation of cementless total knee arthroplasty. We hypothesized that local bisphosphonate (zoledronate) or systemic denosumab would both decrease implant migration. METHODS: This four-way, double-blinded, randomized trial included 108 patients with primary knee osteoarthritis with a five-year follow-up. Three groups had the same cementless total knee tibial implant and were included in this primary study (n = 82). Patients were randomized to either placebo (n = 27), intraoperative local zoledronate (n = 28), or postoperative denosumab (n = 27). The primary outcome was tibial implant migration measured by radiostereometric analysis (RSA) using maximum total point motion (MTPM) and signed migrations. Secondary outcomes were biochemical bone markers (resorption: serum collagen type 1 cross-linked C-telopeptide (CTX); formation: serum type 1 procollagen N-terminal (P1NP)), periprosthetic bone mineral density (BMD), and patient-reported outcomes. RESULTS: At one year, the mean difference in MTPM between zoledronate and placebo was 0.43 mm (95% CI 0.01 to 0.85; p = 0.043), and 0.42 mm (95% CI 0.00 to 0.83; p = 0.048) between denosumab and placebo. At five years, the intervention groups showed less y-translation (subsidence) than placebo: mean difference of 0.50 mm for zoledronate (95% CI 0.23 to 0.78; p < 0.001) and 0.30 mm for denosumab (95% CI 0.03 to 0.58; p = 0.031). CTX was lower in the zoledronate group than in the placebo group at two- and six-week follow-up. In the denosumab group, CTX was lower until one year postoperatively. P1NP were similar in the placebo and zoledronate groups, but lower in the denosumab group up to one year postoperatively. Periprosthetic BMD was higher in intervention groups, with a lasting effect in the zoledronate group at five years. CONCLUSION: Both interventions decreased cementless tibial implant migration by suppressing bone resorption. Local zoledronate had a lasting mitigating effect on subsidence and the periprosthetic BMD. Our findings support the use of local intraoperative zoledronate during knee arthroplasty surgery to improve cementless tibial implant fixation and preserve tibial bone. However, multicentre studies and prospective cohort quality studies should be performed for confirmation.
引用
- Linde KN, Rytter S, Langdahl BL, et al. Migration of cementless total knee arthroplasty is mitigated by both local intraoperative zoledronate and postoperative denosumab: a randomized controlled trial. Bone Joint J. 2025. PMID: 40746103. doi:10.1302/0301-620X.107B8.BJJ-2024-1376.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。